The molecular therapeutic targeting paradigm and the concept of synthetic lethality as exemplified by BRCA1/2 mutations and PARP inhibition offer profound opportunities for ovarian cancer drug development and discovery. Here, BRCA1 is linked to ovarian carcinoma.